BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024

Reuters12-18

Dec 17 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O:

CORVUS PHARMACEUTICALS TO ANNOUNCE INTERIM DATA FROM PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS ON DECEMBER 18, 2024

Source text: ID:nGNXqLLNv

Further company coverage: CRVS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492915677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 05:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492915677","market":"us","top_or_hot":-1,"title":"BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Corvus Pharmaceuticals Inc <span>CRVS.O</span>:</p><ul><li><p>CORVUS PHARMACEUTICALS TO ANNOUNCE INTERIM DATA FROM PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS ON DECEMBER 18, 2024</p></li></ul><p>Source text: <span>ID:nGNXqLLNv</span></p><p>Further company coverage: <span>CRVS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 05:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA125V01:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024Dec 17 (Reuters) - Corvus Pharmaceuticals...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA125V01:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA125V01:1","article_id":"2492915677","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492915677","pubTimestamp":1734472113,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024Dec 17 (Reuters) - Corvus Pharmaceuticals","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRVS":"Corvus Pharmaceuticals, Inc.","BK4568":"美国抗疫概念"},"translate_title":"简报-Corvus Pharmaceuticals将于2024年12月18日公布索奎替尼治疗特应性皮炎的安慰剂对照1期临床试验的中期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":0.9},"content_text":"BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024Dec 17 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O:CORVUS PHARMACEUTICALS TO ANNOUNCE INTERIM DATA FROM PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS ON DECEMBER 18, 2024Source text: ID:nGNXqLLNvFurther company coverage: CRVS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492915677"}